The phase 3 RASolute 302 trial shows that daraxonrasib (RMC-6236) significantly improves survival in patients with previously treated metastatic pancreatic cancer compared with standard chemotherapy.
Patients receiving daraxonrasib had a median overall survival of 13.2 months, compared with 6.7 months for chemotherapy, representing a 60% reduction in the risk of death. The drug also improved progression-free survival and showed a manageable safety profile with no new safety concerns.
Daraxonrasib is a “RAS(ON)” inhibitor designed to target multiple common RAS mutations that drive most pancreatic cancers, including G12D, G12V, and G12R. This broader targeting approach helps explain its strong effectiveness in a disease that has historically been very difficult to treat.
Researchers and experts describe the results as a major breakthrough for metastatic pancreatic ductal adenocarcinoma. The developer plans to submit the drug for regulatory approval.